CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 140 enrolled
Drug / intervention
Ramelteon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02560324
NCT02560324Phase 2Completed
CompareCT.gov

Repurposing Melatonin Receptor Agonists as Adjunct Treatments for Smoking Cessation

University of Pennsylvania·interventional·Posted Sep 25, 2015·Updated Nov 4, 2019

In Brief

A Phase 2 clinical trial evaluating Ramelteon and Placebo for Tobacco Use Disorder. Completed, enrolled 140 participants across 1 site.

Detailed Summary

This is a randomized, double-blind, placebo-controlled crossover study to test whether a medication called ramelteon (Brand Name: Remeron) will help smokers quit and whether it reduces sleep problems that smokers experience during a quit attempt.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 25, 2015
Enrollment StartSep 1, 2015
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.8 years ago

Interventions

Ramelteondrug

Placebodrug